Navigation Links
AtheroGenics Reports ARISE Trial Results for AGI-1067

at the most common adverse event was diarrhea-related and there was an observed increase in liver function tests in some patients compared to those on standard of care.

About ARISE

The ARISE (Aggressive Reduction of Inflammation Stops Events) trial is a Phase III, double-blind, placebo-controlled trial in over 6100 patients with a recent acute coronary syndrome (ACS). The trial was conducted in 259 cardiac centers in the United States, United Kingdom, Canada and South Africa. The primary endpoint in the ARISE study was to compare the effect of AGI-1067 to placebo on the time to first incidence of a composite of major adverse cardiovascular events (MACE), specifically cardiovascular death, resuscitated cardiac arrest, myocardial infarction, stroke, need for coronary revascularization and admission to hospital for unstable angina.

About AtheroGenics, Inc. / AstraZeneca Collaboration

AtheroGenics and AstraZeneca have a worldwide collaboration covering the development and commercialization of AGI-1067. After completion of the final analysis, under the terms of the license and collaboration agreement, AstraZeneca has a 45-day period in which to decide whether or not to continue with the collaboration.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. In addition to AGI-1067, the Company has another clinical-stage development program studying AGI-1096, a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinic
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AtheroGenics Reports ARISE Trial Results for AGI
(Date:9/16/2014)... Sept. 16, 2014  Wearable sports and activity ... less than two years, producing a massive amount ... huge opportunity exists for leveraging this data to ... ) introduced a first-of-its-kind wearable analytics platform for ... of clinical research linking activity and health risks, ...
(Date:9/16/2014)... Sept. 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), ... of chronic pain, announced today that it has entered ... (MSKCC) in a series of animal studies for levorphanol, ... extended release form of levorphanol.  Gavril Pasternak, MD, PhD, ... Dr. Pasternak said, "Levorphanol is a ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Henry Schein To Present At The Leerink Partners Services Roundtable 2
(Date:9/16/2014)... York, NY (PRWEB) September 16, 2014 After ... program as one of the premier fertility centers in the ... Paul Gindoff have returned to their hometown of New York ... with Chelsea IVF and Genetics Labs. , Chelsea Fertility ... of becoming a parent in the New York Tri-State Area, ...
(Date:9/16/2014)... New York, NY (PRWEB) September 16, 2014 ... they are actually hungry, but for comfort during times ... consist of fatty, sugar laden treats that may provide ... as well as sabotaging the best laid weight loss ... Diet Plans that provide patients with the skills ...
(Date:9/16/2014)... YELM, Washington (PRWEB) September 16, 2014 ... to attend the Capstone Event in Yelm, Washington, Oct. ... event finishes the year and caps off the remarkable ... around the world in Switzerland, Italy, Australia, South Korea, ... is $1000, half price for children ages 6-19 and ...
(Date:9/16/2014)... 2014 With Pfister Energy Inc as ... Antonio, TX. has been awarded a solar technology contract ... US, including Alaska and Hawaii, U.S. Territories and the ... (EITF) and the Corps of Engineers, Engineering and Support ... to fund renewable and alternative energy projects greater than ...
(Date:9/16/2014)... 2014 Dr. Randy Carlson and ... the Love Your Marriage event is coming to ... helping married couples to better communicate, increase intimacy and have ... evening of fun, encouragement and learning to strengthen your marriage ... 26 – Living Word Bible Church (Mesa), Saturday, Sept. 27 ...
Breaking Medicine News(10 mins):Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 4Health News:Diet Doc Announces Emotional Eaters Diet Plans to Help Patients Break the Cycle for Fast and Permanent Weight Loss 2Health News:Diet Doc Announces Emotional Eaters Diet Plans to Help Patients Break the Cycle for Fast and Permanent Weight Loss 3Health News:Ramtha School Presents Capstone Event in Yelm Oct. 20-26 2Health News:Solar Construction Opportunity at U.S Army Installations Awarded to Pfister Energy & Infinity Development 2Health News:The Intentional Living Center Introduces the Love Your Marriage Night Featuring Dr. Randy Carlson in Arizona 2
... number of Australian HIV cases in the past seven years ... in men having sex with men, and some clear geographic ... research published online for the Medical Journal of Australia. ... at the National Centre in HIV Epidemiology and Clinical Research ...
... of quitting smoking, but are prepared to try and lessen ... ,However, after studying healthcare literature, a team of Cochrane ... to this alternative of cutting down the number of cigarettes. ... has been at helping them to stop smoking completely. But, ...
... Researchers have revealed that combining a non-pyrethroid insecticide, ... to be an effective insecticide-repellent synergy against ... ,A combination of the two had proved ... addition of their respective properties. Mosquito nets soaked ...
... Research Foundation (MDRF), in collaboration with the U.K.-based Oxford ... Centre in Chennai . ,For the people ... products, this is a significant development. For now scientific ... Index (the metabolic speed at which food is converted ...
... a sensible diet, exercise and weight control helps people ... Howard Hughes Medical Institute have found that all these ... pathway in the brain. ,This insulin-like pathway ... body. The pathway is activated when insulin and insulin-like ...
... linked bipolar disorder or manic depression with accelerated shrinking of ... condition defined as recurrent episodes of significant disturbance in moods. ... researchers led by Dr. Andrew McIntosh at the University of ... the grey matter in the brain of people with bipolar ...
Cached Medicine News:Health News:HIV Cases Increasing In Australia 2Health News:Chain Smokers Prepared to Lessen Their Daily Cigs Rather Than Quitting 2Health News:Insecticide and Repellent Combo Effective in Eliminating Malarial Mosquitoes 2Health News:A Centre for Glycemic Index Testing Opened in Chennai 2Health News:Sensible Diet, Exercise and Weight Control Increases Longevity 2Health News:Sensible Diet, Exercise and Weight Control Increases Longevity 3
... The Veris physiological monitor offers a comprehensive ... specifically designed for pediatric and neonate patients, ... to 3T. Veris is the first MR ... of pediatric and neonate patient monitoring. The ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
... is a fully automated ... for clotting, photometric and ... tests.The medium-throughput analyser offers ... tubes, 45 reagents onboard, ...
Medicine Products: